Evaluation of ability of OR51T1 expression to predict primary hormone therapy efficacy among men with hormone-naive metastatic prostate cancer.

被引：0
|
作者：
Mochizuki, Taku
Miyoshi, Yasuhide
Kawahara, Takashi
Yokomizo, Yumiko
Hayashi, Narihiko
Yao, Masahiro
Miyamoto, Hiroshi
Uemura, Hiroji
机构：
[1] Yokohama City Univ Med Ctr, Yokohama, Kanagawa, Japan
[2] Yokohama City Univ Grad Sch Med, Yokohama, Kanagawa, Japan
[3] Johns Hopkins Sch Med, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.317
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
317
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Expression of PD-L1 in Hormone-naive and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide
    Calagua, Carla
    Russo, Joshua
    Sun, Yue
    Schaefer, Rachel
    Lis, Rosina
    Zhang, Zhenwei
    Mahoney, Kathleen
    Bubley, Glenn J.
    Loda, Massimo
    Taplin, Mary-Ellen
    Balk, Steven P.
    Ye, Huihui
    CLINICAL CANCER RESEARCH, 2017, 23 (22) : 6812 - 6822
  • [42] Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naive Prostate Cancer: A Systematic Review and Network Meta-analysis
    Wallis, Christopher J. D.
    Klaassen, Zachary
    Bhindi, Bimal
    Goldberg, Hanan
    Chandrasekar, Thenappan
    Farrell, Ann M.
    Boorjian, Stephen A.
    Kulkarni, Girish S.
    Karnes, Robert Jeffrey
    Satkunasivam, Raj
    EUROPEAN UROLOGY, 2018, 73 (06) : 834 - 844
  • [43] PI3K/Akt activity regulates androgen receptor expression and predicts poor clinical outcome in non-metastatic hormone-naive prostate cancer
    Blom, Sami
    Maki-Teeri, Petra
    Erickson, Andrew
    Paavolainen, Lassi
    Mirtti, Tuomas
    Rannikko, Antti
    Potdar, Swapnil
    Ostling, Paivi
    van Weerden, Wytske
    Kallioniemi, Olli
    Pellinen, Teijo
    CANCER RESEARCH, 2017, 77
  • [44] Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk
    Arun A. Azad
    Andrew J. Armstrong
    Antonio Alcaraz
    Russell Z. Szmulewitz
    Daniel P. Petrylak
    Jeffrey Holzbeierlein
    Arnauld Villers
    Boris Alekseev
    Taro Iguchi
    Neal D. Shore
    Francisco Gomez-Veiga
    Brad Rosbrook
    Ho-Jin Lee
    Gabriel P. Haas
    Arnulf Stenzl
    Prostate Cancer and Prostatic Diseases, 2022, 25 : 274 - 282
  • [45] Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk
    Azad, Arun A.
    Armstrong, Andrew J.
    Alcaraz, Antonio
    Szmulewitz, Russell Z.
    Petrylak, Daniel P.
    Holzbeierlein, Jeffrey
    Villers, Arnauld
    Alekseev, Boris
    Iguchi, Taro
    Shore, Neal D.
    Gomez-Veiga, Francisco
    Rosbrook, Brad
    Lee, Ho-Jin
    Haas, Gabriel P.
    Stenzl, Arnulf
    PROSTATE CANCER AND PROSTATIC DISEASES, 2022, 25 (02) : 274 - 282
  • [46] LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.
    Fizazi, Karim
    Namphuong Tran
    Enrique Fein, Luis
    Matsubara, Nobuaki
    Rodriguez Antolin, Alfredo
    Alekseev, Boris Y.
    Ozguroglu, Mustafa
    Ye, Dingwei
    Feyerabend, Susan
    Protheroe, Andrew
    De Porre, Peter
    Kheoh, Thian
    Park, Youn C.
    Todd, Mary Beth
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (18)
  • [47] ERG expression can predict the outcome of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer
    Kuronya, Zsofia
    Sukosd, Farkas
    Varga, Linda
    Biro, Krisztina
    Gyergyay, Fruzsina
    Geczi, Lajos
    Nagyivanyi, Krisztian
    Jorgo, Kliton
    Szarvas, Tibor
    Kovacs, Agnes
    Laczo, Ibolya
    Varga, Zoltan
    Posfai, Boglarka
    Pepo, Judit
    Maraz, Aniko
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (04) : 289.e1 - 289.e9
  • [48] Expression of the Androgen-Regulated Fusion Gene TMPRSS2-ERG Does Not Predict Response to Endocrine Treatment in Hormone-Naive, Node-Positive Prostate Cancer
    Boormans, Joost L.
    Hermans, Karin G.
    Ziel-van der Made, Angelique C. J.
    van Leenders, Geert J. H. L.
    Wildhagen, Mark F.
    Collette, Laurence
    Schroeder, Fritz H.
    Trapman, Jan
    Verhagen, Paul C. M. S.
    EUROPEAN UROLOGY, 2010, 57 (05) : 830 - 835
  • [49] p53 and Cyclooxygenase-2 Expression are Directly Associated with Cyclin D1 Expression in Radical Prostatectomy Specimens of Patients with Hormone-Naive Prostate Cancer
    Vlachostergios, Panagiotis J.
    Karasavvidou, Foteini
    Patrikidou, Anna
    Voutsadakis, Ioannis A.
    Kakkas, Grigorios
    Moutzouris, George
    Zintzaras, Elias
    Daliani, Danai D.
    Melekos, Michael D.
    Papandreou, Christos N.
    PATHOLOGY & ONCOLOGY RESEARCH, 2012, 18 (02) : 245 - 252
  • [50] Consecutive Prostate-Specific Membrane Antigen (PSMA) and Antigen Receptor (AR) PET Imaging Shows Positive Correlation with AR and PSMA Protein Expression in Primary Hormone-Naive Prostate Cancer
    al Jalali, Valentin
    Wasinger, Gabriel
    Rasul, Sazan
    Grubmueller, Bernhard
    Wulkersdorfer, Beatrix
    Balber, Theresa
    Mitterhauser, Markus
    Simon, Judit
    Hacker, Marcus
    Shariat, Shahrokh
    Egger, Gerda
    Zeitlinger, Markus
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (06) : 863 - 868
12345